Results 101 to 110 of about 1,397,668 (331)

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Rehabilitation Impact of Vivifrail Exercise Program Type C on the Cognitive Function of Pre-Frail Elderly People in the Community

Folia Medica Indonesiana
Highlights: 1. This study emphasizes the importance of providing physical exercises to pre-frail elderly individuals, especially in a community setting. 2.
Sri Soenarti, Dwi Indriani Lestari, Muhammad Barlian Nugroho, Harien Lestari, Tita Hariyanti   +4 more
doaj   +1 more source

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold

Health Technology Assessment, 2015
Background: Cost-effectiveness analysis involves the comparison of the incremental cost-effectiveness ratio of a new technology, which is more costly than existing alternatives, with the cost-effectiveness threshold.
Karl Claxton, Steve Martin, Marta Soares, Nigel Rice, Eldon Spackman, Sebastian Hinde, Nancy Devlin, Peter C Smith, Mark Sculpher   +8 more
doaj   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Cost-Benefit Estimation of Cadaveric Kidney Transplantation, the Case of a Developing Country [PDF]

In this paper we estimate cost savings for the health-care system and quality of life improvement for patients from an increase in the number of kidney transplants in Chile. To do so, we compare the present value of dialysis and transplantation costs and
Javier Dominguez, Rodrigo Harrison
core  

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Productivity and quality-adjusted life years: QALYs, PALYs and beyond

, 2023
We develop a unified framework for the measurement and valuation of health and productivity. Within this framework, we characterize evaluation functions allowing for compromises between the classical quality-adjusted life years (QALYs) and its polar productivity-adjusted life years (PALYs).
Schultz Hansen, Kristian, Moreno-Ternero, Juan D., Østerdal, Lars Peter   +2 more
openaire   +3 more sources

Cost-effectiveness analysis of applying the Cholesterol and Recurrent Events (CARE) study protocol in Hong Kong. [PDF]

, 2001
OBJECTIVE: To determine the cost-effectiveness of secondary prevention with pravastatin in Hong Kong patients with coronary heart disease and average cholesterol levels.
Chau, J, Cheung, BM, Kumana, CR, Lau, CP, Lauder, IJ, McGhee, SM   +5 more
core  

Where’s WALY? : A proof of concept study of the ‘wellbeing adjusted life year’ using secondary analysis of cross-sectional survey data [PDF]

, 2016
Background The Quality-Adjusted Life Year (QALY) is a measure that combines life extension and health improvement in a single score, reflecting preferences around different types of health gain.
A Appels, A Clarke, A Zajacova, Aileen Clarke, Chris Stinton, D Papaioannou, D Watson, David Jenkinson, DM Crone, EL Idler, EuroQoL Group, F Taggart, FA Huppert, G Lindsay, GR Barton, H Maheswaran, HJ Braiden, HM Agt van, J Brazier, J Brazier, J Collins, J Powell, J Schnittker, J Tosh, JA Johnson, Jason Madan, JHP Hoffmeyer-Zlotnik, JM Haro, KB DeSalvo, L Longworth, L Longworth, M Bharmal, M Herdman, MF Janseen, MJ Crawford, MS Kaplan, N Odou, NP Hurst, P Dolan, P Kind, P Kind, R Brooks, R Core Team, R Rabin, R Tennant, Rebecca Johnson, Sarah Stewart-Brown, SI Saarni, Sian Taylor-Phillips, X Robin, Y Chida   +50 more
core   +3 more sources

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source